AnteoTech Narrows Half-Year Loss Despite Sharp Revenue Fall on Contract Timing

The latest announcement is out from AnteoTech Ltd ( (AU:ADO) ).

AnteoTech Ltd has released its interim financial report for the half year ended 31 December 2025, detailing a sharp fall in reported revenue from ordinary activities alongside a narrower loss. Revenue from ordinary activities declined 85% to $97,000, largely due to timing of sales under a five-year US$1.8 million supply agreement with Serum Institute of India, while total revenue and other income fell 15% to $2.7 million and the net loss narrowed 36% to $1.4 million.

Excluding Serum Institute of India, sales to other customers rose 6%, indicating underlying demand growth despite headline revenue volatility linked to contract timing. The group paid no dividend, and net tangible assets per share dropped to 0.07 cents from 0.28 cents, underscoring continued balance-sheet pressure even as losses moderate and the company works to commercialise its battery and life sciences technologies.

The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

More about AnteoTech Ltd

AnteoTech Ltd is an Australian supplier of advanced material solutions serving the battery materials and life sciences markets. The company leverages its proprietary binding chemistry platform to develop products such as Anteo X binders and Ultranode high-silicon anode formulations for batteries, and AnteoBind activation materials used by vaccine and diagnostic-test manufacturers to deliver more sensitive and reliable results.

Average Trading Volume: 2,882,382

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$38.65M

See more insights into ADO stock on TipRanks’ Stock Analysis page.